SuperworthAbbott Laboratories ABT
- Market cap
- $179.4B
- PE
- 38.7×
- 10y median 36.7×
- Forward PE
- 17.7×
- 10y median 23.8×
- Price to sales
- n/m
- Q3 FY26 missing
- EV/EBIT
- 28.2×
- Revenue, 12 months
- n/m
- Q3 FY26 missing
- Net margin
- n/m
- Q3 FY26 missing
- Free cash flow yield
- n/m
- Q3 FY26 missing
Abbott Laboratories trades at 38.7× trailing earnings, near its ten-year median.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $10.2B+2% | $10B+2% | $10.4B+4% | $10.6B+5% | $11B+7% | $10.4B+4% | $11.1B+7% | $11.4B+7% | $11.5B+4% | $11.2B+8% | $12.6B+13% | n/a | |
| Cost of revenue | $4.6B−1% | $4.5B+3% | $4.6B+3% | $4.7B+2% | $4.9B+9% | $4.5B+0% | $4.9B+6% | $5.1B+8% | $4.9B−0% | $4.9B+9% | $5.3B+10% | n/a |
| Gross profit | $5.7B+3% | $5.5B+2% | $5.8B+5% | $5.9B+7% | $6B+6% | $5.9B+7% | $6.3B+9% | $6.3B+6% | $6.5B+8% | $6.3B+7% | $7.3B+16% | n/a |
| R&D | $700M−3% | $684M+5% | $698M−2% | $713M+6% | $749M+7% | $716M+5% | $725M+4% | $766M+7% | $735M−2% | $767M+7% | $892M+23% | n/a |
| SG&A | $2.7B−8% | $3B+7% | $2.9B+7% | $2.9B+6% | $2.9B+7% | $3.1B+3% | $3.1B+5% | $3.1B+5% | $3.1B+8% | $3.7B+22% | $4B+30% | $4.3B+40% |
| $1.8B+37% | $1.4B−8% | $1.7B+8% | $1.9B+13% | $1.9B+7% | $1.7B+22% | $2.1B+23% | $2.1B+11% | $2.3B+18% | $1.3B−21% | $1.7B−18% | $1.4B−34% | |
| Interest expense | $159M+3% | $141M−8% | $140M−12% | $142M−15% | $136M−15% | $131M−7% | $121M−14% | $121M−15% | $120M−12% | $174M+33% | $351M+190% | n/a |
| Pre-tax income | $1.8B+36% | $1.4B−8% | $1.6B−2% | $1.9B+16% | $2B+13% | $1.8B+24% | $2.1B+34% | $2.2B+12% | $2.4B+16% | $1.4B−19% | $1.5B−29% | $1.2B−44% |
| $201M−30% | $211M−14% | $305M+17% | $294M+25% | −$7.2B | $453M+115% | $371M+22% | $536M+82% | $582M | $372M−18% | $596M+61% | n/a | |
| Net income | $1.6B+54% | $1.2B−7% | $1.3B−5% | $1.6B+15% | $9.2B+479% | $1.3B+8% | $1.8B+37% | $1.6B−0% | $1.8B−81% | $1.1B−19% | $928M−48% | n/a |
| $0.91+54% | $0.70−7% | $0.74−5% | $0.94+15% | $5.27+479% | $0.76+9% | $1.01+37% | $0.94+0% | $1.01−81% | $0.61−20% | $0.53−48% | $0.53−44% | |
| 1.7B−0% | 1.7B−0% | 1.8B+0% | 1.7B+0% | 1.7B−0% | 1.7B−0% | 1.8B+0% | 1.7B+0% | 1.7B+0% | 1.7B+0% | 1.7B−0% | 1.7B−1% |
Gross profit: 73 periods, Q2 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: 7 periods, Q3 FY11 to Q3 FY13: not printed by the filing, worked out from its own lines. 6 periods, Q4 FY20 to Q4 FY25: printed in the fourth-quarter results release.
EPS, diluted: 4 periods, Q4 FY08 to Q4 FY12: quarter's net income to common over its shares, to the cent. 7 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
Diluted shares: 10 periods, Q4 FY08 to Q4 FY19: share-days: the 12-month average less the 9-month, weighted by days. 7 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release. Q4 FY17: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet. Figures from older filings without data tags, and from a results release before its 10-Q, are read from the document's text and checked against it.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q4 FY26 | $13.2B | $12.4B to $13.5B | $1.64 | $1.05 to $1.72 | 16 |
| Q1 FY27 | $12.6B | $12.3B to $12.8B | $1.23 | $0.88 to $1.34 | 12 |
| Q2 FY27 | $13.3B | $13B to $13.5B | $1.43 | $1.38 to $1.46 | 5 |
| Q3 FY27 | $13.8B | $13.4B to $14B | $1.54 | $1.48 to $1.57 | 5 |
| Q4 FY27 | $14B | $13.6B to $14.2B | $1.73 | $1.67 to $1.77 | 5 |
| Q1 FY28 | $13.4B | $13B to $13.6B | $1.36 | $1.31 to $1.39 | 6 |
| Q2 FY28 | $14.2B | $13.8B to $14.4B | $1.57 | $1.51 to $1.60 | 6 |
| Q3 FY28 | $14.7B | $14.3B to $14.9B | $1.70 | $1.64 to $1.74 | 6 |
Peers
Companies in Medical - Devices nearest Abbott Laboratories' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ABTAbbott Laboratories | $179.4B | 38.7× | 36.7× | 17.7× | n/m | n/m | n/m |
| MDTMedtronic | $122B | 23.4× | 28.2× | 15.9× | 3.3× | +10% | 13.9% |
| SYKStryker | $117.8B | 31.8× | 41.2× | 19.3× | 4.6× | +8% | 14.4% |
| BSXBoston Scientific | $66.2B | 18.5× | 67.0× | 14.1× | 3.2× | +14% | 17.5% |
| EWEdwards Lifesciences | $51.3B | 51.2× | 40.3× | 28.3× | 7.9× | +15% | 15.4% |
| GEHCGE HealthCare Technologies | $32.3B | 16.4× | 17.0× | 13.8× | 1.5× | +7% | 9.3% |
| DXCMDexCom | $29.4B | 30.9× | 102× | 27.7× | 5.9× | +16% | 20.1% |
| ZBHZimmer Biomet | $18.8B | 24.0× | 31.4× | n/m | 2.2× | +9% | 9.5% |
| Peer median | $51.3B | 24.0× | 40.3× | 17.6× | 3.3× | +10% | 14.4% |
Investors who own it
Investors we follow who held Abbott Laboratories at the end of Jun 30, 2026, from their 13F filings.
- Tom RussoGardner Russo & Quinn0.0% of portfolio
- Polen CapitalPolen Capital0.0% of portfoliotrimmed
More on Abbott Laboratories
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Devices
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .